Alyssa C. Flint
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alyssa C. Flint has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abbi E. Smith
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
135 shared publications - D. Wade Clapp
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
135 shared publications - Dana K. Mitchell
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana
135 shared publications - Henry Mang
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana
135 shared publications - Li Jiang
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
135 shared publications - Steven D. Rhodes
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
135 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (5) , eady8382
Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis
NF2 (neurofibromatosis type 2)–related schwannomatosis (NF2-SWN) is a cancer predisposition syndrome characterized by the development of bilateral vestibular (VS) and spinal schwannomas. While benign, these tumors can cause substantial morbidity, and effective pharmacological treatments remain limited. Here, we demonstrate that genetic ablation of focal adhesion kinase ( Fak/Ptk2 ) impairs tumor formation and preserves hearing in a murine model of NF2. Mechanistically, we show that Fak deletion decreases macrophage infiltration, attenuates nucleotide-binding oligomerization domain–containing protein 2–, leucine rich repeats (LRR)- and pyrin domain–containing protein 3 inflammasome activation, and suppresses the hepatocyte growth factor–MET axis. Pharmacological inhibition of FAK with single agent VS-4718 did not significantly reduce macroscopic tumor volume; however, its use in combination with the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib resulted in both a significant reduction in tumor volume and the preservation of dorsal root ganglion architecture. Our findings establish a critical role for FAK in schwannoma development and provide rationale for evaluation of combination FAK plus MEK inhibition in future clinical trials for NF2-associated SWN.
- 30 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (5) , eady8382
Open AccessInhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis
NF2 (neurofibromatosis type 2)–related schwannomatosis (NF2-SWN) is a cancer predisposition syndrome characterized by the development of bilateral vestibular (VS) and spinal schwannomas. While benign, these tumors can cause substantial morbidity, and effective pharmacological treatments remain limited. Here, we demonstrate that genetic ablation of focal adhesion kinase ( Fak/Ptk2 ) impairs tumor formation and preserves hearing in a murine model of NF2. Mechanistically, we show that Fak deletion decreases macrophage infiltration, attenuates nucleotide-binding oligomerization domain–containing protein 2–, leucine rich repeats (LRR)- and pyrin domain–containing protein 3 inflammasome activation, and suppresses the hepatocyte growth factor–MET axis. Pharmacological inhibition of FAK with single agent VS-4718 did not significantly reduce macroscopic tumor volume; however, its use in combination with the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib resulted in both a significant reduction in tumor volume and the preservation of dorsal root ganglion architecture. Our findings establish a critical role for FAK in schwannoma development and provide rationale for evaluation of combination FAK plus MEK inhibition in future clinical trials for NF2-associated SWN.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Hallmark KRAS Pathway Heatmap and Top DEGs
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Hallmark KRAS Pathway Heatmap and Top DEGs
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Kaplan Meier Survival Curve and Tolerability
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Kaplan Meier Survival Curve and Tolerability
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
CSF1R Mouse IHC, CSF1R and STK10 Western Blot, CDK6 Human, phospho-Rb (S807/811) Human, and pRSK1 (S380) Human IHC
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
CSF1R Mouse IHC, CSF1R and STK10 Western Blot, CDK6 Human, phospho-Rb (S807/811) Human, and pRSK1 (S380) Human IHC
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Etv4, Dusp6, Phlda1, and Dusp4 mRNA expression
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Etv4, Dusp6, Phlda1, and Dusp4 mRNA expression
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Dosing and schedule of abemaciclib and LY3214996
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Dosing and schedule of abemaciclib and LY3214996
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Gene set enrichment analysis of RAS signatures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Gene set enrichment analysis of RAS signatures
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Pharmacokinetic Evaluation of abemaciclib and LY3214996
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Pharmacokinetic Evaluation of abemaciclib and LY3214996
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma